AKT1 and B-cell chronic lymphocytic leukemia: A controversial impairment of AKT and ERK activation by BCR triggering in CLL cells of patients treated with ibrutinib for 9 mo has been reported (Woyach et al., 2014b) and was allegedly caused by anergic features of these samples, manifesting in a lack of responsiveness to BCR stimulation also at the pretreatment stage in many instances (Apollonio et al., 2013).